• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Aeolus Announces Presentation of Pharmacometric Analysis

    Bryan Mc Govern
    Sep. 26, 2017 08:23AM PST
    Biotech Investing

    Aeolus Pharmaceuticals announced the presentation of new data on AEOL 10150 for the treatment of the pulmonary effects of acute radiation syndrome.

    Aeolus Pharmaceuticals (OTCQB:AOLS) announced the presentation of new data on AEOL 10150 for the treatment of the pulmonary effects of acute radiation syndrome.
    As quoted in the press release:

    The analysis, performed by Jogarao Gobburu, PhD, Vijay Ivaturi, PhD and Hechuan Wang, MS with the Center for Translational Medicine at the University of Maryland School of Pharmacy and funded by Aeolus’ Lung ARS development contract with the Biomedical Advanced Research and Development Authority (“BARDA”) confirmed the statistical significance of the improvement in survival and underlying pathophysiology seen after treatment with AEOL 10150 in NHP efficacy studies conducted by and previously reported by Thomas MacVittie, PhD at the University of Maryland School of Medicine (“UMSOM”).
    Dr. Gobburu’s analysis of data from NHP and mouse efficacy studies, performed under the BARDA contract, concluded that administration of AEOL 10150 for 60 days beginning 24 hours after exposure to lethal radiation provided the best survival benefit and that this level of efficacy demonstrated in an “adequate and well designed” study would likely produce a dose modification factor supporting approval under the Animal Rule.

    Click here to read the full press release.

    Source: www.accesswire.com

    barda contract
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Albireo to Receive More than $55 Million in Nondilutive Cash Payments

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×